domingo, 21 de junio de 2020

COVID-19: Hetero, Cipla get nod to manufacture, market antiviral drug remdesivir | India News,The Indian Express

COVID-19: Hetero, Cipla get nod to manufacture, market antiviral drug remdesivir | India News,The Indian Express

remdesivir covid treatment, remdesivir india covid treatment, remdesivir supply, remdesivir shortage,

COVID-19: Hetero, Cipla get nod to manufacture, market antiviral drug remdesivir

Cipla and Hetero Labs have already entered into non-exclusive licensing agreements with US pharma giant Gilead Sciences, which is the patent holder of the drug remdesivir.

Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)